Traders should monitor for exchange approvals and the final implementation of the share consolidation, which could affect liquidity and stock volatility. The small market cap makes XRTX susceptible to speculative moves around structural changes.
Price Chart
Executive Summary
XORTX Therapeutics has delayed its planned 1-for-5 share consolidation from March 27, 2026, to April 6, 2026, pending final approvals from the TSX Venture Exchange and Nasdaq. The delay introduces uncertainty around the timing of capital structure changes for this micro-cap pharmaceutical company with multiple late-stage kidney disease programs in development.
Key Facts
- XORTX delayed its 1-for-5 share consolidation from March 27, 2026, to April 6, 2026.
- The share consolidation remains subject to approval by the TSX Venture Exchange and Nasdaq.
- The company is developing three clinical-stage therapies: XRx-026 (gout), XRx-008 (ADPKD), and XRx-101 (acute kidney injury).
- XRTX has a market cap of $3M and trades on Nasdaq, TSXV, and Frankfurt exchanges.
Financial Impact
No immediate financial impact; potential reduction in share count by 80% upon completion of consolidation.
Risk Factors
- Risk that TSXV or Nasdaq may not approve the consolidation, leading to further delays or cancellation.
- Low market cap and thin trading volume could amplify volatility post-consolidation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263445 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 17d ago | 6-K | $1.41 | awaiting T+20 | — | $0.8500 (−39.72%) |
Sep 18, 2026 5w ago | 6-K | $1.92 $1.24 | ▼ −35.42% | ▼ −35.62% | $0.8500 (−55.73%) |
Sep 18, 2026 5w ago | Press Release | $1.92 $1.24 | ▼ −35.42% | ▼ −35.62% | $0.8500 (−55.73%) |
Sep 4, 2026 7w ago | 6-K | $2.31 $1.70 | ▲ +26.41% | ▲ +27.01% | $0.8500 (+63.20%) |
Aug 28, 2026 8w ago | 6-K | $2.34 $1.71 | ▼ −26.86% | ▼ −27.12% | $0.8500 (−63.64%) |
Aug 3, 2026 11w ago | 6-K | $2.16 $2.16 | · 0.00% | ▲ +1.24% | $0.8500 (−60.65%) |
Jul 29, 2026 12w ago | 6-K | $2.06 $2.22 | ▲ +7.67% | ▲ +2.65% | $0.8500 (−58.74%) |
Jun 15, 2026 19w ago | 6-K | $2.19 $2.03 | ▼ −7.31% | ▼ −6.56% | $0.8500 (−61.19%) |
Jun 12, 2026 19w ago | 6-K | $2.19 $2.03 | ▼ −7.31% | ▼ −6.56% | $0.8500 (−61.19%) |
May 19, 2026 22w ago | 6-K / PRESS-RELEASE | $2.32 $2.15 | ▲ +7.33% | ▲ +8.31% | $0.8500 (+63.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers